期刊文献+

低剂量吉西他滨治疗晚期非小细胞肺癌的疗效观察和对肺功能的影响 被引量:2

Clinical observation on gemcitabine 6h prolonged infusion regimen in the treatment of advanced non-small-cell lung cancer
下载PDF
导出
摘要 目的:比较低剂量吉西他滨6小时延时GP方案和常规GP方案的疗效、毒性和对肺功能的影响。方法:50例经病理或细胞学确诊的晚期非小细胞肺癌患者,随机分为延时GP方案和常规GP方案两组,其中30例患者化疗前后行肺功能检测,观察两方案疗效、毒性和对肺功能影响的差异。结果:延时组和常规组的近期有效率分别为32%和28%(P>0·05);中位疾病进展时间分别为7·4个月和7·5个月(P>0·05);1年生存率为32%和28%(P>0·05)。延时组Ⅲ-Ⅳ度的白细胞和血小板毒性均低于常规组(分别为20%vs48%,12%vs40%,P均<0·05);对肺功能的影响,延时组的FEV1/VC的升高率和TLCO的下降率亦均低于常规组(P<0·05)。结论:低剂量吉西他滨延时GP方案和常规GP方案,近期及远期疗效无统计学差异,但有更低的Ⅲ-Ⅳ度白细胞和血小板毒性;吉西他滨延时GP方案对肺功能的影响小于常规GP方案。 Objective:1. To evaluate and compare the response, toxicity and lung function in advanced non-small-cell lung cancer patients treated by different GP regimen. Methods: 1.50 patients with advanced NSCLC were randomly divided into two groups, which accepted gemeitabine 6h prolonged infusion GP regimen (25 case ) or thirty-minute infusion GP regimen (25 case ) respectively. 2. lung function of 30 patients were detected before and after chemotherapy. Results: h The response and toxicity of two group : The response rate of 6-h prolonged infusion group was 32% , and the response rate of thirty-minute infusion group was 28% ( P〉0. 05 ) . ②Median time to progressive disease were 7.4 months and 7.5 months in 6h prolonged group and in thirty-minute group ( P〉0.05 ) ; 1-year survival rate were 32 and 28% , respectively (P 〉0. 05).③ Hematologic toxicity: grade 3 and 4 neutropenia oecured more frequently in thirty-minute infusion group( 48% ) compared with 6h prolonged group (20%) (P〈0. 05 ) ; grade 3 and 4 thrombocytopenia oeeured more frequently in thirty-minute infusion group (40%) compared with 6h prolonged group( 12% ) (P〈0. 05). 2. The effect on lung function: The rate of increase of FEVJVC and the rate of decrease of TLCO in thirty-minute infusion group were higher than those of 6h prolonged infusion group ( P〈0. 05 ). Conclusion : Compared with thirty-minute infusion GP regimen, 6h prolonged infusion GP regimen has less grade 3 and 4 thrombocytopenia, neutropenia and lung toxicity.
出处 《临床肿瘤学杂志》 CAS 2005年第6期643-646,共4页 Chinese Clinical Oncology
关键词 吉西他滨 延时低剂量注射 疗效 毒性 肺功能 非小细胞肺癌 Gemcitabine Prolonged-infusion Response Toxicity Lung function Non-small cel lung cancer
  • 相关文献

参考文献10

  • 1Konstantin Akrivakis,Peter schmid,Bernd Flath,et al.Prolonged infusion of gemcitabine in stage Ⅳ breast cancer:a phase Ⅰ study [J].Anti-ancer Drugs ,1999,10:525-531.
  • 2Peter schmid,Konstantin Akrivakis,Bernd Flath,et al.Phase Ⅱ trial of gemcitabine as prolonged infusion in metastatic breast cancer [J].Anti-cancer Drugs,1999,10:625 - 631.
  • 3Rizzieri DA,Bass AJ,Rosner GL,et al.Phase Ⅰ evalution of prolonged - infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia [J].J Clin Oncol 2002; 20 (3):674 - 679.
  • 4K.W.Mass,Van der,K.Bolt,Lung function changes and pulmonary complications in patients with stage Ⅲ non-small-cell lung cancer treated with gemcitabine/cisplatine as part of combined modality treatment [J].Lung Cancer,2003,41,345 -351.
  • 5Heinermann V,Schukz L,Issels RD.Gemcitabine:a modulator of intracellular nucleotide and deoxynucleotide metabolism [J].Semin Oncol 1995,22(suppl 11):11 - 18.
  • 6Plunkett W,Huang P,Xu YZ,et al.Gemcitabine:metabolism,mechanisms of action,and self-potentitation [J].Semin oncol 1995; 22(suppl 11) :3 -10.
  • 7Huang P,Plunkett W.Induction of apoptosis by gemcitabine[J].Semin Oncol 1995,22 (suppl 11):19 - 25.
  • 8Grunewald R,Abbruzzese JL,TarassoffP.Saturation of 2' ,2' -difluorodeoxycytidine 5' -triphosphate accumulation by mononuclear cells during a phase Ⅰ trial of gemcitabine [J].Cancer Chemother Pharmacol,1991,27:258 -262.
  • 9Grunewald R,Kantarjian H,Keating M,et al.Pharmacologically directed design of the dose rate and schedule of 2' ,2' - difluorodeoxycitidine (gemcitabine) administration in leukemia [J].Cancer Res,1990,50:6823 - 6826.
  • 10Veerman G,Ruiz Haperen,Vermorken JB.Antitumor activity of prolonged as compared with bolus administration of 2' ,2' - difluorodexycytidine in vivo against murine colon tumors cancer[J].Chemother Pharmacol,38 (4):335 - 342.

同被引文献21

  • 1蔡少华,王雅娟,张晓军,李洪霞,孙红,俞森洋,刘长庭.吉西他滨致严重肺毒性和全身性毛细血管漏综合征1例[J].中国药物应用与监测,2004,1(4):37-41. 被引量:2
  • 2周怡,张金花,赵卫国.肺癌病人最大呼吸流速容量曲线及弥散功能变化的意义[J].中国医学工程,2007,15(2):169-171. 被引量:7
  • 3Margaritora S, Cesario A, Gusumano G, eta al. Is pulmonaryfunction damaged by neoadjuvant lung cancer therapy? A compre-hensive serial time-trend analysis of pulmonary function after in-duction radiochemotherapy plus surgery [J] ? J Thoracic and Car-diovascular Surgery,2010,139(6) :1457 - 1463.
  • 4Baser S,Shannon VR,Eapen GA,et al. Smoking cessation afterdiagnosis of lung cancer is associated with a beneficial effect onperformance status[ J]. Chest,2006,130(7) : 1784 - 1790.
  • 5Patricia R,Frank C, Mark A,et al. Impact of preoperative chemo-therapy on pulmonary function tests in respectable early-stagenon-small cell lung cancer [ J ]. Chest, 2009,135 ( 6 ) : 1588-1595.
  • 6V aKid B,Marik PE. Pulmonary complications of novel antineo-plastic agents for solid tumors [ J ]. Chest,2008 ,133 ( 2 ) : 528-538.
  • 7Takeda S,Funakoshi Y, Kadota Y, et al. Fall in diffusing capaci-ty associated with induction therapy for lung cancer:a predictor ofpostoperative complication? [J]. Ann Thorac Surg, 2006, 82(1):232 -236.
  • 8Margaritora S,Cesario A,Gusumano G,et al.Is pulmonary function damaged by neoadjuvant lung cancer therapy A comprehensive serial time-trend analysis of pulmonary function after induction radiochemotherapy plus surgery[J].The Journal of Thoracic and Cardiovascular Surgery,2010,139(6):1457.
  • 9Takeda S,Funakoshi Y,Kadota Y,et al.Fall in diffusing capacity associated with induction therapy for lung cancer:a predictor of postoperative complication[J].Ann Thorac Surg,2006,82:232.
  • 10Baser S,Shannon VR,Eapen GA,et al.Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status[J].Chest,2006,130:1784.

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部